Pasithea Therapeutics Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on September 3, 2025, specifically the Company's 2025 Annual Meeting of Stockholders. Pasithea Therapeutics Corp. is an emerging growth company incorporated in Delaware, with its principal executive offices in Miami Beach, Florida. The filing details corporate governance actions, including director elections, auditor ratification, and significant amendments to equity plans and the Certificate of Incorporation.
Key Financial Metrics
The filing text does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
At the Annual Meeting, 3,495,116 shares were represented out of 7,443,577 outstanding shares, constituting a quorum. Stockholders approved four key proposals:
- Director Elections: Alfred Novak and Simon Dumesnil were elected as Class II directors for a three-year term.
- Auditor Ratification: CBIZ CPAs P.C. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Stock Incentive Plan Amendment: The 2023 Stock Incentive Plan was amended to increase the number of authorized shares by 1,750,000, bringing the total to 2,014,221 shares.
- Reverse Stock Split Authorization: The Board was granted authority to effect a reverse stock split of Common Stock at a ratio between 1:2 and 1:20 at any time within one year of the meeting, without further shareholder approval.
Outlook, Risks, and Management Commentary
Management commentary is limited to the execution of the Annual Meeting agenda. The approval of the reverse stock split authorization indicates a strategic intent to potentially adjust the share structure to meet listing requirements or improve market perception, though the specific ratio and timing remain at the Board's discretion. No specific risks or contingencies beyond standard corporate governance matters were detailed in this filing.
Key Facts for Investor Verification
- Verify the exact reverse stock split ratio and implementation date once determined by the Board, as this will impact share count and price per share.
- Monitor the utilization of the newly authorized 1,750,000 shares under the amended 2023 Stock Incentive Plan for potential dilution.
- Review the full text of the Plan Amendment (Exhibit 10.1) for specific terms regarding vesting and eligibility.
- Confirm the Company's continued compliance with Nasdaq Capital Market listing standards following the potential reverse split.